The primary efficacy endpoint was change from baseline MADRS rating. This limited-term study found that, compared to intranasal placebo additionally oral antidepressant, intranasal esketamine in conjunction with an oral antidepressant noticeably improved depressive signs or symptoms immediately after four weeks by a necessarily mean variation of fo